Form 8-K - Current report:
SEC Accession No. 0000950170-25-103026
Filing Date
2025-08-05
Accepted
2025-08-05 16:07:20
Documents
12
Period of Report
2025-08-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K rare-20250805.htm   iXBRL 8-K 48643
2 EX-99.1 rare-ex99_1.htm EX-99.1 332656
3 GRAPHIC img45776771_0.jpg GRAPHIC 24299
  Complete submission text file 0000950170-25-103026.txt   537180

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT rare-20250805.xsd EX-101.SCH 23898
14 EXTRACTED XBRL INSTANCE DOCUMENT rare-20250805_htm.xml XML 4516
Mailing Address 60 LEVERONI COURT NOVATO CA 94949
Business Address 60 LEVERONI COURT NOVATO CA 94949 415-483-8800
Ultragenyx Pharmaceutical Inc. (Filer) CIK: 0001515673 (see all company filings)

EIN.: 272546083 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36276 | Film No.: 251184960
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)